Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review.
Alprostadil
Drug Interaction
Erectile Dysfunction
PGE1
Transdermal Prostaglandin
Journal
Sexual medicine reviews
ISSN: 2050-0521
Titre abrégé: Sex Med Rev
Pays: Netherlands
ID NLM: 101614773
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
29
03
2022
revised:
05
06
2022
accepted:
09
06
2022
entrez:
9
10
2022
pubmed:
10
10
2022
medline:
12
10
2022
Statut:
ppublish
Résumé
Erectile dysfunction (ED) is a substantial cause of dissatisfaction among many men. This discontentment has led to the emergence of various drug treatment options for this problem. Unfortunately, due to various interactions, contraindications, and side effects, systemic therapies such as phosphodiesterase-5 inhibitors (including sildenafil, tadalafil, vardenafil, avanafil, etc.) are not welcomed in many patients. These problems have led researchers to look for other ways to reduce these complications. This article holistically reviews the efficacy of topical prostaglandins and their role in treating ED. We sought to provide a comprehensive overview of recent findings on the current topic by using the extensive literature search to identify the latest scientific reports on the topic. In this regard, topical and transdermal treatments can be suitable alternatives. In diverse studies, prostaglandins, remarkably PGE1 (also known as alprostadil), have been suggested to be an acceptable candidate for topical treatment. Numerous formulations of PGE1 have been used to treat patients so far. Still, in general, with the evolution of classical formulation methods toward modern techniques (such as using nanocarriers and skin permeability enhancers), the probability of treatment success also increases. Hamzehnejadi M, Tavakoli MR, Homayoun F et al. Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review. Sex Med Rev 2022;10:764-781.
Identifiants
pubmed: 36210096
pii: S2050-0521(22)00054-3
doi: 10.1016/j.sxmr.2022.06.004
pii:
doi:
Substances chimiques
Prostaglandins
0
Vardenafil Dihydrochloride
5O8R96XMH7
Tadalafil
742SXX0ICT
Sildenafil Citrate
BW9B0ZE037
Cyclic Nucleotide Phosphodiesterases, Type 5
EC 3.1.4.35
Alprostadil
F5TD010360
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
764-781Informations de copyright
Copyright © 2022 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.